Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05579249 · ClinicalTrials.gov registry record · Phase 4
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
A Phase 4 study of Obesity, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT05579249 is a Phase 4 study of Obesity that has completed, run by Novo Nordisk A/S. The registered enrollment target is 500 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05579249, a Phase 4 study of Obesity, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers. These employers represent employees of diverse demography and job functions including hospitality, clerical, administrative, housekeeping, maintenance, and specialised employees across a range of socioeconomic and educational backgrounds. The study will also look at how weight loss affects physical functioning, quality of life and ability to work. It will also gather information on how satisfied participants are with the medication they take. Participants will either receive semaglutide or one of 4 approved anti-obesity medication (Xenical/Qsymia/Contrave/Saxenda).
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Liraglutide
- DRUG Orlistat
- DRUG Phentermine/Topiramate
- DRUG Naltrexone/Bupropion
Study Locations (1)
California
- Nutrition Research Centre - Loma Linda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-01-19 |
| Est. Completion | 2024-11-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05579249
The ClinicalTrials.gov registry entry for NCT05579249 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (39% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 5 interventions - of which Semaglutide is the first listed.
NCT05579249 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05579249 about?
NCT05579249 is a clinical study titled "A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America". The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers. These employers represent employees of diverse demography and job functions including hospit...
What is the current status of trial NCT05579249?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2023-01-19. Estimated completion is 2024-11-27.
What conditions does trial NCT05579249 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT05579249?
The interventions under investigation include: Semaglutide (DRUG), Liraglutide (DRUG), Orlistat (DRUG), Phentermine/Topiramate (DRUG), Naltrexone/Bupropion (DRUG).
Who is sponsoring clinical trial NCT05579249?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05579249 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.